Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug ...

A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related ...

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

Eli Lilly shares fell up to 10% after Q3 earnings missed Wall Street expectations, reporting $11.4 billion in revenue and ...

ABC News reports a 17.5% increase in asthma-related hospitalization in the three months after Flovent was discontinued and a 24.1% increase in the next three to six months. Other pharma news covers ...

Protein Diagnostics MarketAccording to a recent analysis by Future Market Insights (FMI), the global protein diagnostics market is poised for substantial growth over the coming decade, with an ...

It's a very busy and spooky Halloween eve today — several companies had big misses in earnings reported this morning. Let's ...

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...